Healthcare

ILLUMINA INC

Ticker: ILMN
Exchange: US
Composite FIGI: BBG000DSMS70

Total Alternative Signals

3signals tracked

Weighted Sentiment

+0.43weighted index

Avg Materiality Score

2.3/ 5.0 scale

Signal Distribution

1|2|0

Alternative Data Signal Feed

Real-Time Ingestion Active

Unlock Alternative Signals Feed

Access the complete, parsed materiality analysis, long-term investment theses, and direct feed links for ILLUMINA INC. Programmatic API and Webhooks available.

Talent PivotNeutral
Filing Date: 2026-06-20

Signal Event Report - FIGI BBG000DSMS70

Illumina Inc. filed an 8-K detailing the results of matters submitted to a shareholder vote, likely including the election of directors and other corporate governance proposals, which could influence the company's leadership and strategic direction.

Quantitative Investment Thesis

This filing provides an update on corporate governance, potentially including board composition. Without specific details on the voting outcomes, it does not immediately alter the long-term investment thesis for Illumina Inc., but future analysis of the filing content would be necessary.

Materiality & Sentiment Scores
Sentiment: 0
Materiality: 2 / 5
Source Document: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001110803&type=&dateb=&owner=exclude&count=40
Talent PivotNeutral
Filing Date: 2026-06-16

Signal Event Report - FIGI BBG000DSMS70

A routine Form 4 filing indicating changes in beneficial ownership of securities by an insider of Illumina.

Quantitative Investment Thesis

This routine insider transaction filing does not significantly alter the long-term investment thesis for Illumina without further details on the specific insider or transaction size.

Materiality & Sentiment Scores
Sentiment: 0
Materiality: 1 / 5
Source Document: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001110803&type=&dateb=&owner=include&count=40
Strategic PartnershipBullish
Filing Date: 2026-06-08

Signal Event Report - FIGI BBG000DSMS70

Illumina announced new collaborations with Integrated DNA Technologies and SPT Labtech, alongside the launch of a whole-genome-based MRD research kit for oncology. These initiatives expand its oncology offerings and automation capabilities.

Quantitative Investment Thesis

These strategic partnerships and the launch of an oncology research kit strengthen Illumina's leadership in genomics and expand its addressable market in cancer diagnostics, reinforcing a long-term growth investment thesis.

Materiality & Sentiment Scores
Sentiment: 0.75
Materiality: 4 / 5
Source Document: https://finance.yahoo.com/markets/stocks/articles/illumina-ilmn-valuation-check-oncology-180829817.html?.tsrc=rss